Indian vaccine manufacturers, including SII, Bharat Biotech, Panacea Biotech, Sanofi's Shanta Biotech, Biological E, Hester Biosciences and Zydus Cadila, have an installed capacity to manufacture 8.2 billion doses of different vaccines per year

Stocks in focus in today's trade: TCS, Infosys, Balrampur Chini Mills, Pharma stocks, Barbeque Nation Hospitality and more

Over 91.15% of patients treated with PegIFN were found to be RT PCR negative by day 7 as compared to 78.90 per cent on the 'standard of care' arm; PegIFN reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate COVID-19 patients

Shares of Reliance, SBI, Future Retail, Dalmia Bharat, Vedanta, SBI Cards will be in focus in Monday's trading session

Shares of Craftsman Automation, Anupam Rasayan, Laxmi Organic Industries, Adani Green, Cadila, TVS Motors, Bank of India, Jubilant FoodWorks will be in focus in Thursday's trading session

Share of Cadila Healthcare rose up to 1.15% to Rs 436.05 against previous close of Rs 431.05 on BSE

This move to further revise the prices will go a long way in helping patients during these critical times, the company said.

Stock Market News Update Today: The BSE Sensex witnessed broader-based selling with 28 out of 30 BSE index heavyweights ending in red amid fear that second and third wave infections in India are bound to hamper economic recovery

So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy

Growth in the Indian pharma market is expected to be linear ahead. The market has now grown for the fifth consecutive month and the momentum is likely to improve

Rhizen has retained commercialisation rights for India while also being the manufacturing and supply partner for Umbralisib. Alembic owns 50 per cent stake in Rhizen

Cadila says its business in India, which comprises human health formulations, consumer wellness and animal health, posted strong growth during the quarter as it rose 20 per cent on a y-o-y basis and recorded revenues of Rs 1,643 crore

COVID-19 vaccine: About 19 vaccines are going to be globally available in the coming few weeks and months. Of this, about nine have already got emergency use authorisation

Stocks to watch today on January 25: RIL, YES Bank, JM Financial, Gland Pharma, JSW Steel, Tata Motors among others are the top stocks to watch out for in Monday's trading session

Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Liothyronine Sodium tablets USP, 5 mcg, 25 mcg, and 50 mcg, Cadila Healthcare said in a regulatory filing

There were no serious side effects in the participants enrolled for the phase 1 trial of Covaxin, according to the results published in The Lancet

Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia's Sputnik-V vaccine

Initial 30 crore vaccinations (60 crore doses) planned by the Centre would have cost Rs 13,200 crore. However, need for 66 crore doses raises the cost by Rs 1320 crore

Tarun Arora, CEO, Zydus Wellness said that the company, to begin with, is investing massively to improve the penetration of the Complan brand in mass markets

(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing